Traders cheered Aurobindo's in-line performance by sending the stock nearly 4 percent higher. But they punished Sun Pharma for missing Street estimates across the board by sending the stock down over 6 percent. CNBC-TV18's Ekta Batra and Archana Shukla crunch the numbers.
first published: May 31, 2016 09:54 pm
A collection of the most-viewed Moneycontrol videos.
Groww CEO Lalit Keshre on ₹62,000 Crore IPO, Sebi regulations, valuation expectation and more
How Income Plus Arbitrage Fund of Fund Can Help You Get Stable, Tax-Efficient Returns
Nifty fails to hold 26,000, slips below 25,900 | Closing Bell
Live: Will Nifty bulls take it to new highs after Fed outcome? | Opening Bell
